Allergies and adverse reactions Document
Relevant diagnostic tests/laboratory data note
Patient Goals, preferences, and priorities for care experience
Product containing cilazapril (medicinal product)
Product containing lisinopril (medicinal product)
Ultraproct - cinchocaine 0.5% (5 mg/g) + fluocortolone hexanoate 0.095% (945 microgram/g) + fluocortolone pivalate 0.092% (918 microgram/g) ointment
apply a small amount to the affected area up to 4 times daily on the first day, then twice daily for at least 1 week; continue for up to a maximum of 4 weeks
Influenza, split virus, trivalent, preservative
COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose
Cholesterol.total/Cholesterol in HDL [Molar ratio] in Serum or Plasma
A combined CVD risk of which lipids is one component should be estimated to guide CVD risk management decisions. If lipid modifying medication is considered suggest checking first for treatable secondary causes of dyslipidaemia.
Cholesterol in LDL [Moles/volume] in Serum or Plasma by calculation
Triglyceride [Moles/volume] in Serum or Plasma
Cholesterol [Moles/volume] in Serum or Plasma
Cholesterol in HDL [Moles/volume] in Serum or Plasma
Blood pressure panel with all children optional
Hip prosthesis, device (physical object)
Achieved weight loss to mitigate diabetes risk.